Explore life science companies operating throughout Greater London, from biotechnology startups to global pharmaceutical organisations.
Personalised cancer treatment selection using in vivo drug screening
Vivan Therapeutics is a London-based biotech developing a personalised cancer therapeutics platform. The company's Personal Discovery Process sequences a patient's tumour genome, engineers those mutations into a fruit fly avatar model, and screens thousands of approved drug combinations at high throughput to identify…
AI-powered RNAi drug discovery company developing hepatic medicines
Tangram Therapeutics is a biotechnology company combining artificial intelligence and RNA interference to discover and develop novel medicines. Its proprietary chemistry platform silences disease-driving genes in hepatocytes, and its AI platform drives target identification and siRNA design. The pipeline includes…
XF-73 antimicrobial advancing towards Phase 3 infection prevention
AMR Bio is a clinical-stage biotechnology company developing the XF-73 antimicrobial platform for preventing hospital-acquired infections. Its lead nasal formulation aims to reduce Staphylococcus aureus carriage before surgery. Following Phase 2b clinical testing, the programme is preparing for Phase 3 development.…
Human in vitro models for disease and drug research
Queen Mary Centre for Predictive in vitro Models is a multidisciplinary research centre developing human-relevant laboratory models for studying disease and evaluating potential treatments. Its researchers combine organ-on-a-chip systems, organoids, three-dimensional cell cultures and bioengineering methods to…
AI-powered gut microbiome analysis for personalised clinical nutrition
Enbiosis is a biotechnology company combining whole-genome gut microbiome sequencing with artificial intelligence to generate personalised nutrition, dietary, and supplement recommendations for patients with gastrointestinal disorders. Its B2B platform is used by healthcare professionals including gastroenterologists…
Engineered bacterial immunotherapies for solid tumours
Prokarium is a clinical-stage biopharmaceutical company developing microbial immunotherapies using engineered Salmonella strains. Its platform combines synthetic biology with AI-enabled discovery to create programmable bacterial therapeutics that deliver payloads within the tumour microenvironment. The lead programme…
AI-designed aptamer therapeutics for undruggable targets
PentaBind is a TechBio company using generative AI to design aptamers with drug-like properties for targets that are inaccessible to conventional modalities. Its platform combines proprietary datasets with wet-laboratory validation to deliver multi-attribute aptamer candidates in a fraction of the time and cost of…
Specialist CNS and psychiatric clinical trial design and delivery organisation
Clerkenwell Health is a London-based specialist contract research organisation providing clinical trial design, regulatory submission, and trial delivery services for CNS, psychiatric, and psychedelic-assisted therapy research. The company operates a purpose-built clinical site network, including an NHS-embedded…
Clinical-stage antibody-drug conjugate specialist targeting solid tumours
Pheon Therapeutics is a clinical-stage biotechnology company developing a pipeline of antibody-drug conjugates for the treatment of solid tumours. The company combines monoclonal antibodies with proprietary cytotoxic payloads and linker technologies, taking a target-specific approach to optimising each construct for…
AI clinical decision support for macular and retinal disease
Macusoft is a London-based health technology company developing AI-powered software to support clinical decision-making in ophthalmology. Its platform assists with diagnosis, triage, and treatment recommendations for macular diseases, diabetic retinopathy, and related retinal conditions, drawing on imaging data and…
Intranasal anti-CD3 immunotherapy for neuroinflammatory diseases
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing immunomodulatory therapies for neurological and inflammatory diseases. Its lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody designed to modulate T-cell activity through nasal administration. The 48-patient…
Gene therapies targeting the ageing process and age-related disease
Genflow Biosciences is a longevity-focused biotechnology company developing gene therapies designed to slow or halt the biological ageing process and delay age-related disease. Its lead compound uses an adeno-associated viral vector to deliver a centenarian variant of the SIRT6 gene, with a pipeline spanning human and…
AI epigenomics platform for neurodegenerative disease detection
Prima Mente is a biotechnology company developing large-scale biological foundation models to understand and detect neurodegenerative disease. The company generates proprietary multi-omic data including whole-epigenome sequencing, and trains transformer-based models on DNA methylation patterns in cell-free DNA to…
Clinical trial development, early-phase research and regulatory consulting
Parexel is a global contract research organisation providing clinical trial delivery, early-phase research, regulatory consulting, biostatistics and pharmacovigilance services to pharmaceutical and biotechnology companies. Its UK operations include a 45-bed early-phase clinical unit at Northwick Park Hospital in…
Liver-directed RNA medicines to restore function in chronic liver disease
Apterna is a preclinical biotechnology company developing RNA-based medicines to restore function in damaged livers. Its lead programme is a liver-directed therapy, given by injection under the skin every few months, that silences a single gene which limits the liver's ability to recover from injury. Animal studies…
Molecular biology reagents and enzymes for diagnostic and biotech applications
Apto-Gen is a UK manufacturer of high-performance enzymes and molecular biology reagents for integration into PCR, qPCR, NGS, and isothermal amplification assays. Its products serve human diagnostics, veterinary diagnostics, food safety, and environmental testing customers, and are designed for direct integration into…
Engineering algae to produce carbon-neutral biofuels at scale
Phycobloom is an industrial biotechnology company developing genetically engineered algae strains capable of continuously secreting oil for use in sustainable aviation fuel and plastics. Using synthetic biology and gene editing, the company has engineered algae to capture atmospheric CO2 while producing oil without…
DNA nanoprobes for intracellular biomarker profiling in neurodegeneration
Esya Labs is a precision biomarker company using patented DNA nanoprobes to measure ion signatures within intracellular organelles including endosomes and lysosomes. The technology enables ratiometric quantification of subcellular chemical states in living cells, with applications in early detection of…
University genomics core facility for sequencing, single-cell and spatial analysis
The Imperial BRC Genomics Facility is a university core facility supporting translational genomics research. It provides next-generation sequencing, single-cell genomics, spatial transcriptomics and proteomics, alongside experimental design, library preparation and bioinformatics analysis. Its services are used to…
ADC oncology company developing novel spliceosome-modulating payloads
Akari Therapeutics is a clinical-stage biopharma company developing next-generation bi-functional antibody-drug conjugates for cancer treatment. Its proprietary ADC platform centres on PH1, a novel spliceosome-modulating small molecule payload designed to disrupt RNA splicing in tumour cells and activate anti-tumour…